Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up – Should You Buy?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $34.80, but opened at $35.64. Collegium Pharmaceutical shares last traded at $35.6830, with a volume of 304,170 shares.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Weiss Ratings downgraded Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Needham & Company LLC cut their price objective on shares of Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price (up from $46.00) on shares of Collegium Pharmaceutical in a research report on Friday, January 9th. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Barclays decreased their price target on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a report on Friday, January 9th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $53.00.

Collegium Pharmaceutical Trading Up 3.4%

The company’s fifty day simple moving average is $43.71 and its 200-day simple moving average is $41.94. The firm has a market capitalization of $1.14 billion, a PE ratio of 21.03 and a beta of 0.67. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.57 and a quick ratio of 1.48.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The firm had revenue of $205.45 million during the quarter, compared to analysts’ expectations of $206.36 million. During the same quarter last year, the business earned $1.77 EPS. The business’s revenue was up 12.9% compared to the same quarter last year. As a group, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 49,976 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the completion of the sale, the executive vice president owned 71,770 shares of the company’s stock, valued at $2,900,225.70. This trade represents a 41.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.51% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several large investors have recently made changes to their positions in the stock. Illinois Municipal Retirement Fund increased its holdings in Collegium Pharmaceutical by 1.6% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 17,281 shares of the specialty pharmaceutical company’s stock worth $605,000 after purchasing an additional 278 shares during the period. Vident Advisory LLC raised its stake in shares of Collegium Pharmaceutical by 1.9% during the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock worth $541,000 after buying an additional 281 shares during the last quarter. Quadrant Capital Group LLC grew its position in shares of Collegium Pharmaceutical by 4.2% in the fourth quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock valued at $324,000 after purchasing an additional 282 shares during the last quarter. GAMMA Investing LLC increased its position in Collegium Pharmaceutical by 9.6% during the fourth quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock worth $151,000 after buying an additional 285 shares in the last quarter. Finally, Atom Investors LP raised its stake in Collegium Pharmaceutical by 5.0% in the 4th quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock valued at $284,000 after purchasing an additional 294 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.